Toll-interacting protein may affect doxorubicin resistance in hepatocellular carcinoma cell lines

CONCLUSIONS: Our results showed for the first time that silencing TOLLIP in hepatocellular carcinoma cells may help sensitize these cells to doxorubicin and increase the efficacy of chemotherapeutic regimens where doxorubicin is used.PMID:37644370 | DOI:10.1007/s11033-023-08737-2

Source: Molecular Biology Reports - August 29, 2023 Category: Molecular Biology Authors: Ayse Banu Demir Elif Baris Umay Bengi Kaner Hani Alotaibi Nese Atabey Ahmet Koc Source Type: research